Hospital Clinic of Barcelona
Barcelona, 08036, Spain
Location status: Recruiting
NCT Number: NCT05346757
The present study aims to compare effectiveness and cost-effectiveness of the miRFec test with respect to fecal immunochemical test (FIT) for the detection of advanced colorectal neoplasm among individuals participating in colorectal cancer (CRC) screening, surveillance and diagnosis.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Barcelona, 08036, Spain
Location status: Recruiting
The miRFec test -a Gradient Boosting Machine-generated algorithm that includes two fecal miRNAs (miR-421 and miR-27a-3p) and fecal hemoglobin concentration, along with age and gender- is more effective and cost-effective than FIT for the identification of patients with advanced colorectal neoplasm (i.e. colorectal cancer, advanced adenomas or advanced serrated lesions) among individuals participating in colorectal cancer screening and surveillance programs, and diagnosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
Time frame: Through study completion, an average of 3 years
To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced colorectal neoplasm
Time frame: Through study completion, an average of 3 years
To compare the specificity of the miRFec test with respect to FIT
Time frame: Through study completion, an average of 3 years
To compare the sensitivity of the miRFec test with respect to FIT for the detection of colorectal cancer
Time frame: Through study completion, an average of 3 years
To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced adenomas
Time frame: Through study completion, an average of 3 years
To compare the sensitivity of the miRFec test with respect to FIT for the detection of advanced serrated lesions
Time frame: Through study completion, an average of 3 years
To compare the detection rate for advanced colorectal neoplasm of the miRFec test with respect to FIT
Time frame: Through study completion, an average of 3 years
To compare the discrimination capacity of the miRFec score and fecal hemoglobin concentration for the detection of advanced colorectal neoplasm
Time frame: Through study completion, an average of 3 years
To compare the discrimination capacity of the miRFec score and fecal hemoglobin concentration for the detection of colorectal cancer
Time frame: Through study completion, an average of 3 years
To compare the cost (euros) for detecting one advanced colorectal neoplasm using the miRFec test with respect to the corresponding figure using FIT
Contact information is provided by the study sponsor or research team.
Fundacion Clinic per a la Recerca Biomédica
Other
Prospective, Multicenter, Comparative, Paired Study to Validate a microRNA-based Fecal Test for Colorectal Cancer Screening. The miRFec Study
Acronym: miRFec
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04912765
Adenocarcinoma, Carcinoma
Singapore
View Trial DetailsNCT06411691
Colonic Diseases, Colonic Neoplasms
Baltimore, Maryland, United States
View Trial DetailsNCT07736495
Colonic Diseases, Colorectal Cancer
Cairo, Egypt
View Trial DetailsNCT07321106
Advanced Colorectal Cancer, CRC
Duarte, California, United States
View Trial Details